无对比剂磁共振先行前列腺癌筛查:PROSA随机临床试验
PROSA单中心随机对照试验纳入816名无症状男性,比较无对比剂双参数磁共振(bpMRI)先行策略(A组)与PSA阈值触发bpMRI策略(B组)。在759名随机化男性中,A组活检率和临床显著前列腺癌(csPCa)检出率均高于B组,且获益-危害指标和成本效果更优。
要点
- bpMRI先行策略使csPCa检出率相对风险达2.6(95%CI 1.1-6.1;p=0.05)。
- MRI先行策略减少不必要的活检并提高活检效率与分级选择性。
- 该策略每检出1例csPCa的增量成本效果比为€2201.75。
核心结论
- 无对比剂MRI先行筛查路径提高了csPCa检出率,改善了获益-危害指标并显示有利的成本效果。
研究设计与样本
- 单中心随机对照试验,纳入816名49-69岁无症状男性(有前列腺癌家族史者≥40岁),随机分为A组(无论PSA水平均行bpMRI)和B组(PSA≥3 ng/ml或家族史者PSA≥2.5 ng/ml时行bpMRI)。
- 最终759名男性纳入分析,影像与病理评估者设盲,csPCa定义为ISUP分级组≥2。
主要发现
- A组活检率和csPCa检出率分别为10.8%和4.6%,B组分别为5.2%和1.8%。
- csPCa检出率的相对风险为2.6(95%CI 1.1-6.1;p=0.05)。
- 获益-危害指标 favoring MRI-first策略:分级选择性1.89 vs 1.75,活检效率0.74 vs 0.54,活检避免率23.1 vs 11.9。
- 未记录到严重不良事件。
- MRI先行策略每检出1例csPCa的增量成本效果比为€2201.75。
临床怎么用
- 在无症状男性筛查中,可考虑采用无对比剂bpMRI先行策略以提高csPCa检出并减少不必要活检。
局限性
- 单轮设计且随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) has limited accuracy, and it is linked to overdiagnosis. The PROSA trial aimed to evaluate whether a contrast-free biparametric magnetic resonance imaging (bpMRI)-first screening strategy improves the detection of clinically significant PCa (csPCa) as the primary outcome. The secondary outcomes included overall PCa detection, benefit-harm metrics, and cost effectiveness from a health care payer perspective. METHODS: This single-center, randomized controlled trial enrolled 816 asymptomatic men aged 49-69 yr (≥40 yr with a PCa family history). Participants were randomized into two arms: arm A underwent bpMRI regardless of the PSA levels; arm B received bpMRI only if PSA ≥3 ng/ml (or 2.5 ng/ml with a family history). Men with Prostate Imaging Reporting and Data System score ≥3 were directed to a targeted biopsy. Imaging and pathology assessors were blinded; csPCa is defined as International Society of Urological Pathology grade group ≥2. The primary outcomes included csPCa detection, benefit-harm metrics, and cost effectiveness from a health care payer perspective. KEY FINDINGS AND LIMITATIONS: Among 759 randomized men, biopsy and csPCa detection rates were higher in arm A (10.8% and 4.6%, respectively) than in arm B (5.2% and 1.8%, respectively), with a relative risk of 2.6 (95% confidence interval 1.1-6.1; p = 0.05) for the csPCa detection rate. Benefit-harm metrics favored the MRI-first strategy, showing higher grade selectivity (1.89 vs 1.75), biopsy efficiency (0.74 vs 0.54), and biopsy avoidance (23.1 vs 11.9). No serious adverse event was recorded. The MRI-first strategy yielded an incremental cost-effectiveness ratio of €2201.75 per csPCa case detected. Limitations include single-round design and short follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this randomized screening trial, a contrast-free MRI-first pathway improved csPCa detection, enhanced benefit-harm metrics, and showed favorable cost effectiveness.
引用
- Messina E, Borrelli A, Sciarra A, et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol. 2025. PMID: 41412906. doi:10.1016/j.eururo.2025.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。